https://european-biotechnology.net/wp-content/uploads/2026/02/Bildschirmfoto_2022-04-05_um_09.22.12.png542913Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-10 08:52:282026-02-10 17:02:02Bayer: At last, success with coagulation factor XIa in phase 3 stroke trial
https://european-biotechnology.net/wp-content/uploads/2026/02/priyanka-singh-Jt72_opb38I-unsplash-1030x773-1.jpg7731030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-09 16:56:282026-02-09 16:56:28Dublin-based Aerska secures $39M Series A to push RNA medicines into the brain
https://european-biotechnology.net/wp-content/uploads/2026/02/alev-takil-7ojyp-IXW7w-unsplash.jpg480640Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-09 09:05:592026-02-09 09:05:59U.K. life sciences infrastructure gets a boost as London and Cambridge expand
https://european-biotechnology.net/wp-content/uploads/2026/02/pexels-guillaume-falco-1112556-2229887-1030x773-1.jpg7731030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-06 16:16:042026-02-06 16:16:04BioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s disease
https://european-biotechnology.net/wp-content/uploads/2026/02/mackenzie-marco-XG88BYDSDZA-unsplash.jpg427640Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-06 10:48:552026-02-06 10:48:55Agomab goes public on Nasdaq as biotech IPOs top $1bn in a single week
